Terms: = Endocrine gland cancer AND DEK, D6S231E, 7913, ENSG00000124795, P35659 AND Treatment
6 results:
1. PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-dek interaction.
Ray U; Thirusangu P; Jin L; Xiao Y; Pathoulas CL; Staub J; Erskine CL; Dredge K; Hammond E; Block MS; Kaufmann SH; Bakkum-Gamez JN; Shridhar V
Oncogene; 2023 Sep; 42(37):2725-2736. PubMed ID: 37550562
[TBL] [Abstract] [Full Text] [Related]
2. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract] [Full Text] [Related]
3. The dek Oncoprotein Functions in Ovarian cancer Growth and Survival.
Hacker KE; Bolland DE; Tan L; Saha AK; Niknafs YS; Markovitz DM; McLean K
Neoplasia; 2018 Dec; 20(12):1209-1218. PubMed ID: 30412857
[TBL] [Abstract] [Full Text] [Related]
4. treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V; Librizzi R; Trummer C; Theiler G; Stiegler C; Pieber TR; Obermayer-Pietsch B; Pilz S
Metab Brain Dis; 2017 Feb; 32(1):155-161. PubMed ID: 27525431
[TBL] [Abstract] [Full Text] [Related]
5. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin.
Klubo-Gwiezdzinska J; Burman KD; Van Nostrand D; Mete M; Jonklaas J; Wartofsky L
Thyroid; 2012 Mar; 22(3):310-7. PubMed ID: 22313411
[TBL] [Abstract] [Full Text] [Related]
6. Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A.
Cecconi D; Donadelli M; Rinalducci S; Zolla L; Scupoli MT; Scarpa A; Palmieri M; Righetti PG
Proteomics; 2007 May; 7(10):1644-53. PubMed ID: 17443844
[TBL] [Abstract] [Full Text] [Related]
